NAD(P)H: quinone oxidoreductase 1 activatable toll-like receptor 7/8 agonist designed for precise immunotherapy

An NQO1-responsive precursor, named R848-QPA , has been developed to evoke an anti-tumor immune response. R848-QPA can induce innate immune activation when activated by overexpressed NQO1 in the tumor microenvironment while showing lower activity in NQO1-deprived environments. This strategy provides...

Full description

Saved in:
Bibliographic Details
Published in:Chemical communications (Cambridge, England) England), 2023-05, Vol.59 (42), p.6343-6346
Main Authors: Li, Guo, Xu, Yongxiao, Kong, Xiaojie, Gu, Liuwei, Qin, Yuling, Wu, Li
Format: Article
Language:English
Subjects:
Humans
Immune system
NAD
NAD(P)H Dehydrogenase (Quinone)
Neoplasms - drug therapy
Prodrugs - pharmacology
Proteins
Quinones
Quinones - pharmacology
Toll-Like Receptor 7
Tumor Microenvironment
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:An NQO1-responsive precursor, named R848-QPA , has been developed to evoke an anti-tumor immune response. R848-QPA can induce innate immune activation when activated by overexpressed NQO1 in the tumor microenvironment while showing lower activity in NQO1-deprived environments. This strategy provides a new method for the development of tumor-microenvironment-responsive prodrugs for antitumor immunotherapy. An NQO1-responsive agonist has been developed to evoke an anti-tumor immune response, providing a new concept for tumor-microenvironment-responsive prodrug design to achieve precise immunotherapy.
ISSN:1359-7345
1364-548X
DOI:10.1039/d3cc00663h